140 related articles for article (PubMed ID: 16264850)
1. Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?
Saltz LB
Nat Clin Pract Oncol; 2005 Jan; 2(1):20-1. PubMed ID: 16264850
[No Abstract] [Full Text] [Related]
2. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
[TBL] [Abstract][Full Text] [Related]
3. Treatment with cetuximab, bevacizumab and irinotecan in heavily pretreated patients with metastasized colorectal cancer.
Halama N; Herrmann C; Jaeger D; Herrmann T
Anticancer Res; 2008; 28(6B):4111-5. PubMed ID: 19192669
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.
Saltz LB; Lenz HJ; Kindler HL; Hochster HS; Wadler S; Hoff PM; Kemeny NE; Hollywood EM; Gonen M; Quinones M; Morse M; Chen HX
J Clin Oncol; 2007 Oct; 25(29):4557-61. PubMed ID: 17876013
[TBL] [Abstract][Full Text] [Related]
5. Can the addition of cetuximab to irinotecan improve outcome in colorectal cancer?
Rosati G
Nat Clin Pract Gastroenterol Hepatol; 2005 Jan; 2(1):20-1. PubMed ID: 16265095
[No Abstract] [Full Text] [Related]
6. [Application of monoclonal antibody in combination with irinotecan in the treatment of colorectal cancer].
Li J
Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):796-7. PubMed ID: 17366800
[No Abstract] [Full Text] [Related]
7. Assessment of baseline clinical predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer.
Hebbar M; Di Fioré F; Conroy T; Giraud C; Gasnault L; Fournier C; Péreira R; Bouché O; Fournier P; Deligny N; Joly JP; Maes P; Rad E; Michel P; Adenis A
Oncology; 2007; 73(3-4):185-91. PubMed ID: 18418011
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial.
Vincenzi B; Santini D; Rabitti C; Coppola R; Beomonte Zobel B; Trodella L; Tonini G
Br J Cancer; 2006 Mar; 94(6):792-7. PubMed ID: 16508634
[TBL] [Abstract][Full Text] [Related]
9. Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome.
Vincenzi B; Santini D; Galluzzo S; Russo A; Fulfaro F; Silletta M; Battistoni F; Rocci L; Zobel BB; Adamo V; Dicuonzo G; Tonini G
Clin Cancer Res; 2008 Jul; 14(13):4219-24. PubMed ID: 18594003
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer].
Zheng H; Chen JZ; Liao WJ; Luo RC
Nan Fang Yi Ke Da Xue Xue Bao; 2006 May; 26(5):689-91. PubMed ID: 16762887
[TBL] [Abstract][Full Text] [Related]
11. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.
Scartozzi M; Bearzi I; Pierantoni C; Mandolesi A; Loupakis F; Zaniboni A; Catalano V; Quadri A; Zorzi F; Berardi R; Biscotti T; Labianca R; Falcone A; Cascinu S
J Clin Oncol; 2007 Sep; 25(25):3930-5. PubMed ID: 17761976
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab in colon cancer.
Costa AF; Sander GB; Picon PD
N Engl J Med; 2004 Oct; 351(15):1575-6; author reply 1575-6. PubMed ID: 15473024
[No Abstract] [Full Text] [Related]
13. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.
Sobrero AF; Maurel J; Fehrenbacher L; Scheithauer W; Abubakr YA; Lutz MP; Vega-Villegas ME; Eng C; Steinhauer EU; Prausova J; Lenz HJ; Borg C; Middleton G; Kröning H; Luppi G; Kisker O; Zubel A; Langer C; Kopit J; Burris HA
J Clin Oncol; 2008 May; 26(14):2311-9. PubMed ID: 18390971
[TBL] [Abstract][Full Text] [Related]
14. The price tag on progress--chemotherapy for colorectal cancer.
Schrag D
N Engl J Med; 2004 Jul; 351(4):317-9. PubMed ID: 15269308
[No Abstract] [Full Text] [Related]
15. New combinations in metastatic colorectal cancer: what are our expectations?
Hurwitz H
Oncologist; 2005 May; 10(5):320-2. PubMed ID: 15851788
[No Abstract] [Full Text] [Related]
16. Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer.
Roca JM; Alonso V; Pericay C; Escudero P; Salud A; Losa F; López LJ; Guasch I; Méndez M; Quintero-Aldana G; Grande C; Vicente P; Arrivi A; Martin C; Moreno I; García P; Antón I; Constenla M; Yubero A; Cirera L;
Chemotherapy; 2010; 56(2):142-6. PubMed ID: 20407241
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma.
Delbaldo C; Pierga JY; Dieras V; Faivre S; Laurence V; Vedovato JC; Bonnay M; Mueser M; Nolting A; Kovar A; Raymond E
Eur J Cancer; 2005 Aug; 41(12):1739-45. PubMed ID: 16051481
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab in colon cancer.
Martin MJ
N Engl J Med; 2004 Oct; 351(15):1575-6; author reply 1575-6. PubMed ID: 15473023
[No Abstract] [Full Text] [Related]
19. Second-line treatment of patients with metastatic colorectal cancer.
Rougier P; Lepere C
Semin Oncol; 2005 Dec; 32(6 Suppl 9):S48-54. PubMed ID: 16399432
[TBL] [Abstract][Full Text] [Related]
20. Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan.
Vincenzi B; Santini D; Russo A; Gavasci M; Battistoni F; Dicuonzo G; Rocci L; Rosaria VM; Gebbia N; Tonini G
Pharmacogenomics; 2007 Apr; 8(4):319-27. PubMed ID: 17391070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
